STOCK TITAN

Q32 Bio: BVF Partners' deemed stake is about 9.99%

Available on EDGAR Accepted by SEC EDGAR Learn about SEC filing dates
(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Q32 Bio Inc. (QTTB) amendment reports that, as of September 30, 2026, Biotechnology Value Fund, L.P. beneficially owned 1,924,671 shares (approximately 6.3%), Biotechnology Value Fund II, L.P. 929,003 shares (approximately 3.1%), and Biotechnology Value Trading Fund OS LP 155,156 shares (less than 1%). BVF Partners, L.P., BVF Inc. and Mark N. Lampert, a director and officer of BVF Inc., each may be deemed to beneficially own 3,043,222 shares (approximately 9.99%); these are overlapping attributions, not separate blocks.

The reporting persons and a Partners managed account held pre-funded warrants exercisable for 2,341,780 shares. The 9.99% ownership limit restricted exercise to 693,222 of those shares as of September 30, 2026. The reported ownership percentages use 29,769,466 shares outstanding as of August 3, 2026, plus 693,222 shares issuable upon exercise of certain warrants.

Beneficial ownership 3,043,222 shares BVF Partners, L.P., BVF Inc. and Mark N. Lampert each may be deemed to own this amount, approximately 9.99%; attributions overlap.
Beneficial ownership 2,853,674 shares BVF GP Holdings LLC may be deemed to own this amount, approximately 9.4%, as of September 30, 2026.
Beneficial ownership 1,924,671 shares Biotechnology Value Fund, L.P.; approximately 6.3% as of September 30, 2026.
Beneficial ownership 929,003 shares Biotechnology Value Fund II, L.P.; approximately 3.1% as of September 30, 2026.
Beneficial ownership 155,156 shares Biotechnology Value Trading Fund OS LP; less than 1% as of September 30, 2026.
Shares underlying pre-funded warrants 2,341,780 shares Held by the reporting persons and a Partners managed account as of September 30, 2026.
Warrant shares exercisable under ownership limit 693,222 shares Of the 2,341,780 shares underlying warrants, as of September 30, 2026.
Shares outstanding 29,769,466 shares As of August 3, 2026; used with 693,222 shares issuable upon exercise of certain warrants in calculating reported ownership percentages.
Pre-Funded Warrants technical
"Pre-Funded Warrants exercisable for an aggregate of 2,341,780 shares"
Pre-funded warrants are financial instruments that give investors the right to purchase a company's stock at a set price, but with most or all of the purchase price paid upfront. They function like a coupon or gift card for stock, allowing investors to buy shares later at a fixed price, which can be beneficial if they want to avoid future price increases. This makes them important for investors seeking flexibility and certainty in their investment plans.
Ownership Limit technical
"the Ownership Limit limits the exercise of the Pre-Funded Warrants"
beneficially owned financial
"beneficially owned 1,924,671 Shares"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
shared dispositive power technical
"Shared Dispositive Power 1,924,671.00"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many QTTB shares did the reporting entities beneficially own?

As of September 30, 2026, Biotechnology Value Fund, L.P. reported 1,924,671 shares, Biotechnology Value Fund II, L.P. reported 929,003 shares, and Biotechnology Value Trading Fund OS LP reported 155,156 shares. BVF Partners, L.P., BVF Inc. and Mark N. Lampert each may be deemed to own 3,043,222 shares; those attributions overlap.

How many QTTB warrant shares could the reporting parties exercise under the ownership limit?

As of September 30, 2026, the 9.99% ownership limit restricted exercise to 693,222 of the 2,341,780 shares underlying pre-funded warrants held by the reporting persons and a Partners managed account. A holder may not exercise if it and its affiliates would beneficially own more than 9.99% immediately after exercise.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google





746964105

(CUSIP Number)
09/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



BIOTECHNOLOGY VALUE FUND L P
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF I GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BIOTECHNOLOGY VALUE FUND II LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF II GP LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
Biotechnology Value Trading Fund OS LP
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF Partners OS Ltd.
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF GP HOLDINGS LLC
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF PARTNERS L P/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
BVF INC/IL
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert, Authorized Signatory
Date:11/16/2026
LAMPERT MARK N
Signature:/s/ Mark N. Lampert
Name/Title:Mark N. Lampert
Date:11/16/2026

Keep reading